Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

Marc Bourlière (1) , Stuart Gordon (2) , Steven L. Flamm (3) , Curtis Cooper , Alnoor Ramji , Myron Tong , Natarajan Ravendhran , John Vierling (4) , Tram Tran , Stephen Pianko (5) , Meena Bansal , Victor de Ledinghen (6) , Robert Hyland , Luisa Stamm , Hadas Dvory-Sobol , Evguenia Svarovskaia , Jie Zhang , K.C. Huang , G. Mani Subramanian (7) , Diana Brainard , John G. Mchutchison (7) , Elizabeth Verna , Peter Buggisch (8) , Charles S Landis (9) , Ziad Younes (10) , Michael Curry , Simone Strasser , Eugene Schiff (11) , K. Rajender Reddy (12) , Michael Manns (13) , Kris V. Kowdley (14) , Stefan Zeuzem (15)

1 Service d'hépatologie et de gastroentérologie [Hôpital Saint-Joseph - Marseille]
2 Henry Ford Health System
3 Feinberg School of Medicine
4 BCM - Baylor College of Medicine
5 Monash Medical Centre [Clayton, Australia]
6 Département d'hépatologie et de gastroentérologie [CHU Bordeaux]
7 Gilead Sciences, Inc. [Foster City, CA, USA]
8 Institute for Interdisciplinary Medicine Hamburg
9 University of Washington [Seattle]
10 Gastro One
11 MU - Miami University [Ohio]
12 Penn State - Pennsylvania State University
13 Dept. of Gastroenterology, Hepatology, and Endocrinology
14 Virginia Mason Medical Center
15 Saarland University [Saarbrücken]

Domaines: Médecine humaine et pathologie

Marc Bourlière, Stuart Gordon, Steven L. Flamm, Curtis Cooper, Alnoor Ramji, et al.. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. New England Journal of Medicine, 2017, 376 (22), pp.2134-2146. ⟨10.1056/NEJMoa1613512⟩. ⟨hal-02517335⟩